Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.

Date publication

décembre 2017

Journal

Clinical genitourinary cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Pr KURTZ Jean-Emmanuel , Pr LANG Hervé , Dr LINDNER Véronique , Dr THIERY Alicia

Tous les auteurs :
Korenbaum C, Pierard L, Thiéry A, Story F, Lindner V, Lang H, Kurtz JE, Barthélémy P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29395949

Résumé

Metastatic renal cell carcinoma (RCC) with a sarcomatoid component is a rare disease associated with a poor prognosis. We report the outcomes of 47 patients with metastatic sarcomatoid RCC (SRCC) treated with different modalities including chemotherapy, tyrosine kinase inhibitors, or immunotherapy over 2 decades in a French cancer center. Furthermore, we assessed the validity of prognostic scores in this subset of RCC.

Mots clés

Chemotherapy, Immunotherapy, Metastasis, Renal cell carcinoma, Sarcomatoid

Référence

Clin Genitourin Cancer. 2017 Dec 28;: